Clinical Trials Sponsored by Oragenics, Inc

Total 35584 results

Oragenics, Inc.

Terminated

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Oral Mucositis

United Kingdom, United States, Belgium, Germany
TriAgenics Inc

Withdrawn

An Early Feasibility Evaluation of a Novel 3rdMolarTooth Bud Ablation Procedure (3TBA)

Molar, Third
Oragenics, Inc.
University of Washington

Unknown

Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

Oral Health

United States
Progenics Pharmaceuticals, Inc.

Completed

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)

Prostate Cancer

United States, Canada
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Progenics Pharmaceuticals, Inc.

Completed

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer (CONDOR)

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Recurrent | Prostate Cancer Metastatic

United States, Canada
Progenics Pharmaceuticals, Inc.

Completed

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

HIV Infections | Acquired Immune Deficiency Syndrome

United States
Northwestern University
Progenics Pharmaceuticals, Inc.

Recruiting

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Prostate Cancer

United States
Nara Organics
Paidion Research, Inc.

Completed

Growth and Safety Clinical Trial on a New Infant Formula.

Healthy Growth

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Withdrawn

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Opioid-Induced Constipation

Canada, United States, France, Spain
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Opioid-Induced Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Constipation
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Ileus

United States, South Africa, Canada, Hungary, Poland, Australia, Belgium, Germany, Italy, Korea, Republic of, Netherlands
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, United Kingdom, Brazil, Spain, Sweden
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Portugal, United Kingdom
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Constipation

Korea, Republic of, Taiwan
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Stony Brook University
Progenics Pharmaceuticals, Inc.

Completed

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Prostate Cancer

United States
Cordgenics, LLC

Active, not recruiting

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer

United States
Cordgenics, LLC

Completed

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (CSCRGBM)

Recurrent Glioblastoma

United States
Cordgenics, LLC

Suspended

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer (ACSCO)

Recurrent Ovarian Cancer

United States
Jonsson Comprehensive Cancer Center
Progenics Pharmaceuticals, Inc.

Terminated

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)

Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...

United States
Dana-Farber Cancer Institute
Progenics Pharmaceuticals, Inc.

Not yet recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Ashok Muthukrishnan
Progenics Pharmaceuticals, Inc.

Terminated

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Weill Medical College of Cornell University
Progenics Pharmaceuticals, Inc.; Viewray Inc.

Recruiting

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT)

Prostate Cancer

United States, United Kingdom
Alessandro D'Agnolo
Progenics Pharmaceuticals, Inc.

Active, not recruiting

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Genital Diseases, Male | Prostatic Disease

United States
Centre hospitalier de l'Université de Montréal...
Progenics Pharmaceuticals, Inc.

Active, not recruiting

PSMA-PET Guided Radiotherapy (PSMA-PETgRT)

Prostate Cancer

Canada
H. Lee Moffitt Cancer Center and Research Institute
Progenics Pharmaceuticals, Inc.

Recruiting

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Recurrent Prostate Cancer | Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Progenics Pharmaceuticals, Inc.

Completed

Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer

Prostate Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Progenics Pharmaceuticals, Inc.

Not yet recruiting

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Prostate Adenocarcinoma | Castration Resistant Prostate Cancer | Castration Sensitive Prostate Cancer

United States
Heinrich Elinzano, MD
University of Texas; Rhode Island Hospital; Progenics Pharmaceuticals, Inc.

Completed

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Gliosarcoma | GBM

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.

Not yet recruiting

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma

United States
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Progenics...

Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3)

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States

Clinical Trials Sponsored by Oragenics, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations